Apri — Class III drug recall D-1436-2014
Terminated recall by Teva Pharmaceuticals USA, reported 2014-07-23, distributed nationwide. Failed Impurities/Degradation Specifications: out of specification impurity test results.
| Recall number | D-1436-2014 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, North Wales, PA, United States |
| Recall initiated | 2014-06-17 |
| Classified | 2014-07-17 |
| Reported by FDA | 2014-07-23 |
| Terminated | 2015-03-09 |
| Distributed | Nationwide (US) |
| Quantity | 1,104 blister |
| Reason classes | specification failure |
| NDC | 00555-9043, 00555-9043-58, 00555-9043-79 |
| Lot numbers | 11/14, 3805324A |
Product
Apri (desogestrel and ethinyl estradiol tablets USP), 0.15 mg/0.03 mg, 6 Cyclic dispensers X 28 tablets, Rx only, Teva Pharmaceuticals, Sellersville, PA. NDC 0555-9043-58
Reason for recall
Failed Impurities/Degradation Specifications: out of specification impurity test results.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1436-2014. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.